Assignee
OPI VI IP HOLDCO LLC
US·1 granted patent·4 pending applications·6 citations·filing 2016–2021
Top patents by PatentIndex Score
5 records- 0186US10988543B2Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumorOPI VI—IP HOLDCO LLC·Filed 2016·Granted Apr 27, 2021·6 cites·17 claims
- 0260US2021139604A1Compositions of antibody construct-agonist conjugates and methods of use thereofOPI VI IP HOLDCO LLC·Filed 2020·Application pending·0 cites
- 0357US2021301028A1Composition and methods for anti-tnfr2 antibodiesOPI VI IP HOLDCO LLC·Filed 2021·Application pending·0 cites
- 0452US2017298139A1Compositions of antibody construct-agonist conjugates and methods of use thereofOPI VI - IP HOLDCO LLC·Filed 2017·Application pending·0 cites
- 0549US2017158772A1Compositions of antibody construct - agonist conjugates and methods of use thereofOPI VI - IP HOLDCO LLC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when OPI VI IP HOLDCO LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →